GLP-1 Receptor Agonists |ForumIAS

ForumIAS LATEST

1. 1. SFG FRC 2027 | Program starts from 18th Dec. 2026 | Admissions open for Entrance Test Click Here to know more →
  2. Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
  3. [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
  4. 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →

News: WHO has endorsed a new class of drug, GLP-1 Receptor Agonists, for managing obesity.

About GLP-1 Receptor Agonists

Role: They mimic a hormone that regulates appetite and blood sugar level, lipid metabolism, and other biological functions.
Drugs in this class include semaglutide and tirzepatide, which have potential to be transformative.
Utility:
- Helps in treatment of Type 2 diabetes and obesity.
- These drugs can complement current policies promoting healthy eating and physical exercise to curb the obesity pandemic.
- These drugs are significant as obesity affects nearly 1 in 8 people worldwide.
Side Effects: There are severe side effects like stomach paralysis, inflamed pancreas and thyroid cancer.